Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation (Nabi-HB-SC)

This study has been withdrawn prior to enrollment.
(New sponsor's existing product under evaluation for this indication)
Information provided by:
Biotest Pharmaceuticals Corporation Identifier:
First received: November 26, 2008
Last updated: June 29, 2010
Last verified: June 2010

November 26, 2008
June 29, 2010
April 2010
August 2010   (final data collection date for primary outcome measure)
To evaluate the efficacy of Nabi-HB administered subcutaneously weekly for a total of 14 weeks in patients who previously underwent a liver transplant. Levels will provide evidence if effective anti-HB levels >150 IU/ML can be maintained. [ Time Frame: 14 weeks ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00800787 on Archive Site
To evaluate the safety of Nabi-HB administered subcutaneously weekly for a total of 14 weeks. [ Time Frame: 14 weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation
A Phase 3, Multicenter, Open Label Study to Assess the Safety and Efficacy of Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Associated Liver Disease Who Underwent Liver Transplantation

A phase 3, multicenter, open label study to assess the safety and efficacy of Nabi-HB, administered subcutaneously in patients with Hepatitis B Virus Associated Liver Disease who underwent liver transplantation.

This is a phase 3 prospective, single arm open label study to be conducted t approximately 4 study sited located in th e USA. Approximately 25 HBV DNA negative patients who underwent liver transplant at least one year prior, due to chronic hepatitis B infection will bwe eligible for study participation. The study consist of a total of 16 study visit and the duration of participation will be 20 weeks for each patients. Patients will be converted from the intravenous standard HBIG to Nabi-HB subcutaneous administration according to the individual scheduled dosing interval.

Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Chronic Hepatitis B Liver Disease
  • Orthostotic Liver Transplant
Biological: Hepatitis B immune globulin (Human)

Hepatitis b Immune Globulin (Human)(Nabi-HB) 312 IU/L per dose administered subcutaneously.

Dosage will be according to each patients body weight, as follow:

< 75 kg: 500 IU weekly ( may be increase to 1,000 IU weekly if anti-HBs levels are <150 IU/ML > 75 Kg: 1,000 IU weekly

Other Names:
  • Hepatitis B Immune Globulin (Human)
  • Nabi-HB
Experimental: Arm One: Nabi-HB
All subjects will be administered Nabi HB Subcutaneously
Intervention: Biological: Hepatitis B immune globulin (Human)
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
September 2010
August 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female patients 18 years old or older as of visit one.
  • If female is not trying to conserve, not lactating, and has a negative serum pregnancy test and use an acceptable method of contraception or be at least one year post-menopausal or surgically sterile.
  • Able to provide written informed consent.
  • First time liver transplant recipient.
  • Primary, single organ recipient (deceased donor <65 years old).
  • receive regular long-term HBIG prophylaxis with stabilized HBIG dosage and administration intervals.
  • Have negative quantifiable HBV-DNA and HBsAg results prior to dosing at visit 2.
  • Following the last IV administration of HBIG, have a baseline serum anti-HBs level of >150 IU/ML prior to dosing at visit 2.

Exclusion Criteria

  • Positive HCV or HIV test results.
  • Unexplained elevated liver function tests.
  • Serum creatinine level >2.0 times the upper limit of normal.
  • life expectancy <6 months.
  • liver transplantation with ongoing acute rejection episode. Donor liver that was from a hepatitis Bor C positive donor. Underwent a liver transplant <12 months prior to visit 1.
  • Know history of cancer, suspected cancer, or cancer therapy within 12 months.
  • History of autoimmune disease.
  • History/current evidence of coagulation disorder, severe cardiac disease, unhealed gastric or duodenal ulcer, or other significant disease.
  • Evidence of any other unresolved infection and any unresolved opportunistic infection requiring treatment.
  • Known immunoglobulin A deficiency.
  • History of use of immunosupressive or immunomodulatory drug within 3 month prior to visit 1. (except low dose glucocorticoid therapy, <10 mg of prednisone or equivalent per day.)
  • received and investigational drug 30 days prior to visit 1.
  • use of plasma preparations or other immunoglobulins during the study.
  • Know intolerance to proteins of human origin, immunoglobulin, or comparable products.
  • Evidence of alcohol and/or drug abuse within 6 month of visit 2 or inability/unwillingness to abstain from alcohol for the duration of the study.
18 Years to 65 Years
Contact information is only displayed when the study is recruiting subjects
Not Provided
George L. Herrera, MD, Biotest Pharmaceuticals Corporation
Biotest Pharmaceuticals Corporation
Not Provided
Not Provided
Biotest Pharmaceuticals Corporation
June 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP